Would some cannabinoids ameliorate symptoms of autism?

Eur Child Adolesc Psychiatry (2012) 21:237–238
DOI 10.1007/s00787-012-0255-z
LETTER TO THE EDITOR
Would some cannabinoids ameliorate symptoms of autism?
Rami Bou Khalil
Received: 11 December 2011 / Accepted: 1 February 2012 / Published online: 17 February 2012
Ó Springer-Verlag 2012

Eur Child Adolesc Psychiatry (2012) 21:237–238
References
1. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011)
Oxytocin and vasopressin in the human brain: social neuropep-
tides for translational medicine. Nat Rev Neurosci 12:524–538
2. Green JJ, Hollander E (2010) Autism and oxytocin: new devel-
opments in translational approaches to therapeutics. Neurothera-
peutics 7:250–257
3. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu
A (2010) Promoting social behavior with oxytocin in high-
functioning autism spectrum disorders. Proc Natl Acad Sci USA
107:4389–4394
4. Sala M, Braida D, Lentini D et al (2011) Pharmacologic rescue of
impaired cognitive flexibility, social deficits, increased aggres-
sion, and seizure susceptibility in oxytocin receptor null mice: a
neurobehavioral model of autism. Biol Psychiatry 69:875–882
5. Wainwright A, Rutter AR, Seabrook GR, Reilly K, Olivier KR
(2004) Discrete expression of TRPV2 within the hypothalamo-
neurohypophysial system: implications for regulatory activity
within the hypothalamic–pituitary–adrenal axis. J Comp Neurol
474:24–42
6. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J,
Peterson-Zeitz KR (2000) Impaired nociception and pain sensa-
tion in mice lacking the capsaicin receptor. Science 288:306–313
7. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM
(2008) TRPV2 is activated by cannabidiol and mediates CGRP
release in cultured rat dorsal root ganglion neurons. J Neurosci
28:6231–6238
8. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito
G (2009) Cannabidiol in medicine: a review of its therapeutic
potential in CNS disorders. Phytother Res 23:597–602
9. Onaivi ES, Benno R, Halpern T et al (2011) Consequences of can-
nabinoid and monoaminergic system disruption in a mouse model of
autism spectrum disorders. Curr Neuropharmacol 9:209–214
10. Belzung C, Leman S, Vourc’h P, Andres C (2005) Rodents model
for autism: a critical review. Drug Discov Today Dis Models
2:93–101